CRANBURY, N.J.--(BUSINESS WIRE)--June 27, 2006--Valera Pharmaceuticals, Inc. (NASDAQ:VLRX - News) today announced it submitted an Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) for VP004, a subdermal implant utilizing Valera's Hydron technology to deliver naltrexone, over an extended period of time, for the treatment of opioid addiction.
